chufangao/CTO huggingface dataset:
Clinical trial NCT05418803: BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
Official title: An Open-label, Randomized, 2-sequence, 2-period, Fasted, Single Dose, Oral Administration, Crossover Study to Evaluate the Bioequivalence of YHP1807 Tablets 2.5 mg and YHR1901 Tablets 2.5 mg in Healthy Volunteers
Sponsor: Yuhan Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-28
Primary completion date: 2020-02-14
Completion date: 2020-02-14
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to ejsong@yuhan.co.kr.~A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov).
IPD time frame: Beginning 1 year and ending 5 years after all trial endpoints were assessed
IPD access criteria: Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to ejsong@yuhan.co.kr.
Clinical trial NCT02613416: Denosumab and MRI Breast Imaging
Official title: Phase II Correlative Study of Denosumab Effects on Tissue and Imaging Breast Biomarkers
Acronym: Dmab
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-30
Primary completion date: 2021-08-20
Completion date: 2021-08-20
Plan to share individual participant data: NO
Clinical trial NCT03679624: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Official title: A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-30
Primary completion date: 2020-09-15
Completion date: 2020-10-13
Baseline population: 0 subjects were enrolled in Cohort B.
Plan to share individual participant data: NO
Clinical trial NCT00301457: Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
Official title: A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.
Acronym: DATA
Sponsor: Maastricht University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1914.0 (ACTUAL)
Number of arms: 2.0
Start date: 2006-06-30
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Clinical trial NCT02379650: Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
Official title: RCT Assessing Hydroxychloroquine for Unexplained Recurrent Pregnancy Loss
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Testing required by FDA for IND approval was too expensive to move forward with conduct of the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-31
Primary completion date: 2019-07-31
Completion date: 2021-07-31
Clinical trial NCT04763135: Mirtazapine in Cancer-related Poly-symptomatology
Official title: What is the Effectiveness and Safety of Mirtazapine Versus Escitalopram in Alleviating Cancer-associated Poly-symptomatology (MIR-P)? A Mixed-method Randomized Controlled Trial Protocol
Acronym: MIR-P
Sponsor: Hospices Civils de Lyon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: difficulties in recruiting
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-15
Primary completion date: 2021-12-17
Completion date: 2021-12-17
Clinical trial NCT04849858: Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
Official title: Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures: A Quality Improvement Project in Post-operative Pain
Sponsor: University of California, Irvine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-20
Primary completion date: 2023-01-13
Completion date: 2023-01-13
Plan to share individual participant data: NO
Clinical trial NCT05076604: Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Official title: Effects of Microplegia on Transfusion Rates After Cardiac Surgery: A Randomized Prospective Analysis
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 314.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-25
Primary completion date: 2023-06-01
Completion date: 2023-08-01
Plan to share individual participant data: NO
Clinical trial NCT05152459: Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
Official title: A Phase 1/2 Study of Tazemetostat With Umbralisib and Ublituximab in Patients With Relapsed/Refractory Follicular Lymphoma
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Feasibility
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-05-01
Primary completion date: 2024-12-15
Completion date: 2024-12-15
Clinical trial NCT02793219: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
Official title: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Dendreon was sold and new company decided not to fund study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-31
Primary completion date: 2018-07-31
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT03110133: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Official title: A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Acronym: PRISM3
Sponsor: Finch Research and Development LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 206.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-08
Primary completion date: 2020-02-28
Completion date: 2020-06-18
Baseline population: Modified Intent to Treat (mITT) population used
Plan to share individual participant data: NO
Clinical trial NCT02171429: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
Official title: Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Acronym: HIBISCUS II
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 358.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-11-14
Primary completion date: 2020-03-02
Completion date: 2020-05-25
Baseline population: The overall number of baseline participants (716) represents the total number enrolled (358) in this study, GA28949 (NCT02171429), plus the total number enrolled (358) in a second study of identical design, GA28948 (NCT02163759). Some of the pre-specified secondary outcome measure comparisons were planned to be evaluated by pooling data from both studies; all etrolizumab versus adalimumab comparisons and one family of etrolizumab versus placebo comparisons were evaluated on pooled data.
Clinical trial NCT03619655: Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Official title: Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to changing prostate cancer standard of care, the research question became obsolete as the target population for the study no longer existed. The study is deemed not clinically relevant.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-15
Primary completion date: 2022-11-14
Completion date: 2022-11-14
Plan to share individual participant data: NO
Clinical trial NCT02576977: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Official title: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated early due to business reasons
Enrollment: 251.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-19
Primary completion date: 2018-07-09
Completion date: 2020-07-16
Baseline population: The analysis population included all randomized participants.
Limitations and caveats: The MK-3475-183 study was stopped/terminated early. Endpoint statistics may be biased due to the incomplete treatment and follow-up of participants after study termination
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05081375: Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures
Official title: A Blinded, Controlled, Randomized Study of the Safety of Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures
Sponsor: Valleywise Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI left the institution
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-16
Primary completion date: 2023-11-02
Completion date: 2023-11-02
Plan to share individual participant data: NO
Clinical trial NCT03151863: Intranasal Dexmedetomidine for Procedural Pain Management in Elderly Adults in Palliative Care
Official title: Intranasal Dexmedetomidine for Procedural Pain Management in Elderly Adults in Palliative Care Setting: a Cross Over, Superiority, Double-blind, Controlled and Randomized Clinical Trial
Acronym: INDEX
Sponsor: University Hospital, Geneva (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of budget
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-14
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Plan to share individual participant data: UNDECIDED
IPD sharing description: In case of request for a systematic review/meta-analysis, IPD can be shared after publication.
Clinical trial NCT04781647: A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
Official title: A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B
Sponsor: Assembly Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies.
Enrollment: 54.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-02-18
Primary completion date: 2022-12-02
Completion date: 2022-12-02
Limitations and caveats: Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies. As a result, not all subjects completed Week 48 and some outcome measures were impacted.
Plan to share individual participant data: NO
Clinical trial NCT03706274: PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
Official title: A Phase 1, Open-Label, Dose-Ranging Study of the PD-1 Probody Therapeutic CX-188 in Adults With Recurrent or Metastatic Solid Tumors
Sponsor: CytomX Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2020-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to lack of efficacy
Enrollment: 85.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-07
Primary completion date: 2023-12-29
Completion date: 2023-12-29
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Clinical trial NCT04744207: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
Official title: A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)
Sponsor: Gesynta Pharma AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 94.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-29
Primary completion date: 2022-06-15
Completion date: 2022-06-15
Plan to share individual participant data: NO
Clinical trial NCT04903054: Selective CD28 Blockade in Renal Transplant Recipients
Official title: Selective CD28 Blockade With Lulizumab Compared to CNI Inhibition With Tacrolimus in Renal Transplant Recipients
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Limited period of availability of a supply of the study drug and difficulties in enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-10
Primary completion date: 2022-09-22
Completion date: 2022-09-22
Plan to share individual participant data: YES
IPD sharing description: The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD time frame: On average, within 24 months after database lock for the trial.
IPD access criteria: Open access.
Clinical trial NCT04299503: Topical Crisaborole in Patients With Alopecia Areata
Official title: Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients With Mild-to-Moderate Alopecia Areata
Sponsor: Tufts Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to identify subjects to meet inclusion criteria
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-06
Primary completion date: 2022-03-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03187080: Enhanced Recovery Strategies in Elective Breast Surgery
Official title: Evaluating the Use of Enhanced Recovery Strategies and Paravertebral Block in Elective Breast Reduction and Breast Augmentation
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: per Research Hold
Enrollment: 113.0 (ACTUAL)
Number of arms: 8.0
Start date: 2017-10-19
Primary completion date: 2021-06-15
Completion date: 2021-06-15
Baseline population: Study Terminated Early
Limitations and caveats: Study terminated early and not powered for meaningful results.
Plan to share individual participant data: NO
Clinical trial NCT04816916: Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Acronym: EMMPOWER
Sponsor: Axcella Health, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor is stopping the study to focus company resources on other development programs.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-29
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Clinical trial NCT03786094: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Official title: An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Acronym: FORTRESS
Sponsor: Spexis AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was halted early due to failure to meet the primary endpoint.
Enrollment: 432.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-30
Primary completion date: 2021-10-19
Completion date: 2021-10-19
Baseline population: Overall Population (2nd Line+)
Limitations and caveats: The trial was halted early due to failure to meet the primary endpoint.
Clinical trial NCT04159896: ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Official title: Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer
Sponsor: Barbara Ann Karmanos Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-13
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Baseline population: This is a single arm study with run-in phase. All participants, including the run-in phase, received same dose level, so the safety or efficacy will be analyzed in the total n=10 participants as a single group.
Limitations and caveats: Early termination leading to small numbers of subjects analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04360551: Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients
Official title: Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients
Sponsor: University of Hawaii (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Decrease in COVID-19 cases locally
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-01
Primary completion date: 2022-04-26
Completion date: 2022-04-26
Limitations and caveats: The number of individuals involved in the study was extremely small. The study was terminated early because the number of infections in the community substantially decreased.~As an outpatient study, the study only involved individuals with mild to moderate COVID-19 infection, as those severely ill with acute COVID-19 infections may have been hospitalized.
Plan to share individual participant data: YES
Clinical trial NCT04920383: ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Official title: An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)
Acronym: NEON-2
Sponsor: Alpine Immune Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-22
Primary completion date: 2022-11-08
Completion date: 2023-02-28
Clinical trial NCT03654729: Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
Official title: A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC
Acronym: POLAR-M
Sponsor: Egetis Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.
Enrollment: 291.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-07
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Baseline population: Safety analysis set consisting of all randomized patients who received at least one dose of IMP. Patients were analyzed according to the study treatment they actually received.
Plan to share individual participant data: NO
Clinical trial NCT05098327: Pioglitazone and Insulin Resistance in ADT
Official title: Role of Pioglitazone Therapy in Management of Insulin Resistance Associated With Androgen Deprivation Therapy (ADT) in Patients With Prostate Cancer
Sponsor: State University of New York at Buffalo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: no participant enrolled due to lack of interest.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-01
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO